252 related articles for article (PubMed ID: 33513824)
1. Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy.
Zaballos M; Power M; Canal-Alonso MI; González-Nicolás MÁ; Vasquez-Jimenez W; Lozano-Lominchar P; Cabrerizo-Torrente P; Palencia-García N; Gago-Quiroga S; Ginel-Feito MD; Jiménez C; Lázaro A; González-Bayón L
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513824
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
[TBL] [Abstract][Full Text] [Related]
3. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study.
Hakeam HA; Al Duhailib Z; Salahuddin N; Amin T
J Chemother; 2018 Jul; 30(4):224-232. PubMed ID: 29565228
[TBL] [Abstract][Full Text] [Related]
4. Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients - A retrospective analysis.
Vachez E; Kefleyesus A; Bakrin N; Ranchon F; Rioufol C; Vassal O; Al-Hadeedi O; Kepenekian V; Glehen O
Eur J Surg Oncol; 2024 Feb; 50(2):107955. PubMed ID: 38219699
[TBL] [Abstract][Full Text] [Related]
5. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.
Nakamura T; Kokuryo T; Hashimoto Y; Inui KI
J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324
[TBL] [Abstract][Full Text] [Related]
6. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
Owusu-Agyemang P; Arunkumar R; Green H; Hurst D; Landoski K; Hayes-Jordan A
Ann Surg Oncol; 2012 Aug; 19(8):2652-6. PubMed ID: 22451231
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection.
Humanes B; Camaño S; Lara JM; Sabbisetti V; González-Nicolás MÁ; Bonventre JV; Tejedor A; Lázaro A
Nephrol Dial Transplant; 2017 Oct; 32(10):1645-1655. PubMed ID: 28340076
[TBL] [Abstract][Full Text] [Related]
8. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies.
Cascales Campos PA; González-Gil A; Gómez-Ruiz AJ; Gil-Gómez E; Alconchel-Gago F; Navarro-Barrios A; Martínez-García J; Alonso-Romero JL; Nieto A; Barceló-Valcarcel F; Gil-Martínez J
Hernia; 2020 Apr; 24(2):257-263. PubMed ID: 31069579
[TBL] [Abstract][Full Text] [Related]
10. Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity.
Hori Y; Aoki N; Kuwahara S; Hosojima M; Kaseda R; Goto S; Iida T; De S; Kabasawa H; Kaneko R; Aoki H; Tanabe Y; Kagamu H; Narita I; Kikuchi T; Saito A
J Am Soc Nephrol; 2017 Jun; 28(6):1783-1791. PubMed ID: 28052987
[TBL] [Abstract][Full Text] [Related]
11. Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
Chen KL; Shamavonian R; Karpes JB; Alzahrani NA; Morris DL
Anticancer Res; 2021 Mar; 41(3):1641-1646. PubMed ID: 33788760
[TBL] [Abstract][Full Text] [Related]
12. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation.
Markewitz A; Hammer C; Pfeiffer M; Zahn S; Drechsel J; Reichenspurner H; Reichart B
Transplantation; 1994 Mar; 57(6):865-70. PubMed ID: 8154033
[TBL] [Abstract][Full Text] [Related]
13. Assessment of nephrotoxicity associated with combined cisplatin and mitomycin C usage in laparoscopic hyperthermic intraperitoneal chemotherapy.
Kapoor R; Robinson KA; Cata JP; Owusu-Agyemang P; Soliz JM; Hernandez M; Mansfield P; Badgwell B
Int J Hyperthermia; 2019; 36(1):493-498. PubMed ID: 30935256
[TBL] [Abstract][Full Text] [Related]
14. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
Humanes B; Lazaro A; Camano S; Moreno-Gordaliza E; Lazaro JA; Blanco-Codesido M; Lara JM; Ortiz A; Gomez-Gomez MM; Martín-Vasallo P; Tejedor A
Kidney Int; 2012 Sep; 82(6):652-63. PubMed ID: 22718191
[TBL] [Abstract][Full Text] [Related]
15. Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence.
Tejedor A; Torres AM; Castilla M; Lazaro JA; de Lucas C; Caramelo C
Curr Med Res Opin; 2007 Mar; 23(3):505-13. PubMed ID: 17355732
[TBL] [Abstract][Full Text] [Related]
16. Lipidomics Reveals Cisplatin-Induced Renal Lipid Alterations during Acute Kidney Injury and Their Attenuation by Cilastatin.
Moreno-Gordaliza E; Marazuela MD; Pastor Ó; Lázaro A; Gómez-Gómez MM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830406
[TBL] [Abstract][Full Text] [Related]
17. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
18. PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy.
Xie F; Van Bocxlaer J; Colin P; Carlier C; Van Kerschaver O; Weerts J; Denys H; Tummers P; Willaert W; Ceelen W; Vermeulen A
AAPS J; 2020 Jul; 22(5):96. PubMed ID: 32710204
[TBL] [Abstract][Full Text] [Related]
19. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.
Arita M; Watanabe S; Aoki N; Kuwahara S; Suzuki R; Goto S; Abe Y; Takahashi M; Sato M; Hokari S; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Hayashi M; Ohshima Y; Kabasawa H; Hosojima M; Koya T; Saito A; Kikuchi T
Sci Rep; 2021 Jan; 11(1):750. PubMed ID: 33437029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
